N ephrotic syndrome is recognized as a significant cardiovascular disease (CVD) risk factor, associated with hypertension and accelerated atherosclerosis. In fact, the American Heart Association classifies nephrotic syndrome in children as a Tier II CVD risk factor. 1 Primary glomerular diseases such as membranous nephropathy, focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD) often become manifest in individuals when nephrotic syndrome develops, and treatment focuses on decreasing proteinuria and inducing remission. The clinical course of these diseases can include periods of remission and relapse of nephrotic syndrome. Hypertension and CVD are comorbid conditions associated with these entities.
While not completely understood, there are several possible pathophysiologic mechanisms for the development of elevated blood pressure (BP) and hypertension among individuals with primary proteinuric glomerulopathies. Proposed causes include renin-angiotensin-aldosterone system (RAAS) activation, sodium retention, and volume expansion either because of RAAS activation or secondary to a sodium-handling defect. 2 Elevated BP is also caused by medication side effects of corticosteroids and calcineurin inhibitors (CNIs) that are commonly used in the treatment of individuals with proteinuric disease. Despite the increased risk for CVD morbidity and mortality among these individuals, the prevalence of hypertension, antihypertensive treatment patterns, and relationship of hypertension to clinical outcomes in these specific glomerular diseases have not been well described.
Independent of adequate BP control, visit-to-visit BP variability (BPV), defined as the degree of variation between discrete BP readings at separate time points, has been shown to predict cardiovascular morbidity and mortality in the general population and in patients with chronic kidney disease. [3] [4] [5] [6] In addition, greater visit-to-visit BPV has been associated Abstract-Hypertension and blood pressure variability (BPV; SD and average real variability) in primary proteinuric glomerulopathies are not well described. Data were from 433 participants in the NEPTUNE (Nephrotic Syndrome Study Network). Hypertensive BP status was defined as previous history of hypertension or BP ≥140/90 mm Hg for adults/≥95th percentile for children at baseline. BPV was measured in participants with ≥3 visits in the first year. with worse proteinuria and renal function. 7, 8 The relationship between visit-to-visit BPV and renal outcomes in proteinuric glomerular disease is unknown.
To characterize CVD risk factors and antihypertensive treatment patterns among a contemporary cohort of adults and children with primary glomerular diseases that can present with nephrotic syndrome, we studied individuals enrolled in the NEPTUNE (Nephrotic Syndrome Study Network). The goals of this study were (1) to define the prevalence and management of hypertensive BP status in patients with primary proteinuric glomerulopathies across age groups and histological diagnoses and (2) to determine whether hypertensive BP status and BPV were associated with adverse renal outcomes.
Materials and Methods

NEPTUNE (Nephrotic Syndrome Study Network)
The design of the NEPTUNE study has been previously described in detail. 9 In brief, NEPTUNE is a multicenter observational cohort study of children and adults with glomerular diseases that cause nephrotic syndrome. Participants of any age with ≥500 mg/d of proteinuria on a 24-hour urine sample or with a urine protein/creatinine ratio ≥0.5 g/g on a spot urine specimen were enrolled at the time of a clinically indicated kidney biopsy at 21 sites in North America. Patients with kidney manifestations of systemic disease, prior solid organ transplant, or life expectancy <6 months were excluded. There were 470 participants enrolled between July 1, 2010 and May 1, 2016. Participants were assigned to the following disease cohorts based on histological confirmation by core pathologists: MCD, FSGS, membranous nephropathy, or other glomerulopathy, which included IgA nephropathy. 10 Study visits consisted of data and biosample collection at baseline, every 4 months during the first year, and then every 6 months for a total of 5 years. The study protocol was approved by the Institutional Review Board at each participating site, and informed consent/assent was obtained from each participant.
BP Measurements
Casual BP measurements were obtained in triplicate at each study visit using a calibrated oscillometric device. BP was measured in the right arm with the participant in a seated position after 5 minutes of rest. The average of the last 2 readings was used. Participants were classified as hypertensive BP status (HTN) if either of the following criteria were met: (1) a clinical diagnosis of hypertension was recorded in their medical record or (2) their average baseline BP was in the hypertensive range for age. Among the subset of individuals categorized as HTN who had a previous clinical diagnosis of hypertension, those with an average baseline BP either ≥95th percentile for age, sex, and height 11 for children or ≥140 mm Hg systolic or ≥90 mm Hg diastolic 12 for adults were consider to be hypertensive uncontrolled. Those with a clinical diagnosis of hypertension with BPs below these thresholds were considered hypertensive controlled. To allow for comparison across adults and children, a systolic and diastolic BP index was calculated: average measured BP was divided by 140 or 90 as applicable in adults or by the sex-, age-, and height-specific 95th percentile BP in children. Although BP index has not been used previously in adult studies, BP index is a common approach to standardize BP among individuals of different age, sex, and size in the pediatric literature. [13] [14] [15] BP index ≥1 indicates BP in the hypertensive range, and every 0.1 U increase represents a 10% increase in BP above hypertensive range.
Visit-to-visit BPV was calculated using BP measurements obtained during the first year of the study in participants with ≥3 separate visits with a documented BP measurement. We chose to examine 2 metrics of systolic and diastolic BPV: (1) SD which measures overall variability and (2) average real variability (ARV) which measures variability between consecutive visits and was calculated as the mean difference in BP between visits. 16 
CVD Risk Factors, Covariate, and Outcome Measurements
Clinical and demographic characteristics, including immunosuppressive and antihypertensive medication use, urine protein/creatinine ratio, serum creatinine, and self-reported smoking status, were collected from the participants. Children <18 years old were categorized into the pediatric group; all others were categorized as adults. Weight status was classified into normal, overweight, and obese categories based on reference data for body mass index in adults or body mass index percentile in children. 17 The presence of edema was documented by a clinician at each study visit. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease-Epidemiology (CKD-Epi) formula for participants ≥18 years and the modified Schwartz formula for participants <18 years. 18, 19 Renal outcomes that were pre-determined by NEPTUNE included complete remission ever, composite end point, and eGFR slope. Complete remission ever was defined as urine protein/creatinine ratio ≤0.3 at any study visit. The composite end point was defined as development of end-stage renal disease (ESRD) or eGFR decline by ≥40% by the time of the last follow-up. The eGFR slope of the leastsquares regression line was calculated for each person using the first and last serum creatinine measured at least 8 months apart, reported as mL min −1 y −1 .
Statistical Analysis
NEPTUNE participants with BP recorded at the baseline visit were included in this analysis. Adult and pediatric patients were considered separately and then compared. Descriptive statistics were used to describe the demographic and clinical characteristics among the full cohort, stratified by age and histological subgroups based on χ 2 /Fisher exact tests or the Wilcoxon rank-sum/Kruskal-Wallis test for categorical and continuous variables, respectively. Multivariable logistic regression was used to evaluate the association of disease cohort and odds of having HTN for both adults and children adjusting for age, sex, race, weight status (overweight/obese versus not), edema (yes/no), steroid use (yes/no), CNI use (yes/no), eGFR, and smoking status (yes/no; adults only).
To evaluate the association of renal outcomes (eGFR slope, composite end point, and complete remission ever) with HTN and BPV, regression models were used adjusting for age, sex, race, disease cohort, and follow-up time (model 1). A second model (model 2) included those variables from model 1 in addition to smoking status, CNI/steroid use, RAAS use, weight status, edema, cholesterol, and baseline systolic BP index and baseline eGFR. Multiple linear regression based on generalized estimating equations to account for the correlation of individual-level clinical visits was used to determine the relationship between HTN and BPV with eGFR slope. Finally, pooled logistic regression models with a complementary log-log link were used to evaluate the association of HTN and BPV with time to complete remission ever and the composite end point. Results of these analyses are presented as hazard ratios with corresponding 95% confidence interval (CI). The time-to-event analysis started with the baseline visit. The entire follow-up period was used to analyze outcomes where HTN was the primary exposure of interest, whereas a minimum of 2 visits after year 1 in participants was included in the outcome analysis for BPV only. All analyses were conducted using SPSS, version 24 (IBM Inc) and R version 3.3.2.
20 A 2-sided P value of ≤0.05 was considered statistically significant.
Results
Patient Population
There were 443 participants with baseline BP, including 296 adults and 147 children enrolled in NEPTUNE as of May 1, 2016. Cross-sectional baseline demographic and clinical characteristics of the study cohort stratified by age group are summarized in Table 1 . There was a significantly greater proportion of black race and lower prevalence of obese/ overweight in the pediatric group. Diagnosis differed by age group; there was a higher proportion of membranous nephropathy in adults and a higher proportion of MCD in children. Children had a significantly higher eGFR and lower urine protein/creatinine ratio than adults. The pediatric group also had a significantly greater proportion of participants ARV indicates average real variability; BMI, body mass index; BP, blood pressure at baseline; CNI, calcineurin inhibitor; DBP, diastolic BP; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; IQR, interquartile range; MCD, minimal change disease; MN, membranous nephropathy; SBP, systolic BP; and UPC, urine protein:creatinine ratio.
*Other glomerulopathy cohort included diagnoses of membranoproliferative glomerulonephritis, thin basement membrane, complement 1Q, complement 3 glomerulopathy, crescentic glomerulonephritis, mesangial, glomerulosclerosis, membranous with nodular diabetes mellitus, nodular glomerulosclerosis, thrombotic microangiopathy, and indeterminate.
†Hypertensive BP status defined as previous clinical diagnosis of hypertension or an elevated BP for age at the baseline visit; hypertensive uncontrolled defined as previous diagnosis of hypertension and elevated BP at the baseline visit.
‡BP index: BP was divided by 140 or 90 in adults or by the 95th percentile BP in children; an index ≥1 is indicative of a BP in the hypertensive range.
treated with steroids and CNI than the adult group. For the entire cohort, the median follow-up time was 24 months (interquartile range, 12-37 months) with a median of 4 visits (interquartile range, 2-7 visits; 13.8% with 3 visits, 11% with 4 visits, 10% with 5 visits, 9.6% with 6 visits, and 27.9% with ≥7 visits). There was no difference in mean follow-up time between age groups.
Hypertensive BP Status
At baseline, 261 participants (58.9%) had a previous clinical diagnosis of hypertension (n=207) or had baseline BP in the hypertensive range (n=54) and were classified as HTN. Children were disproportionately more likely to be categorized as HTN based on baseline BP than by previous clinical diagnosis of hypertension, 59.4% (n=41/69) versus 40.6% (n=28/69), P=0.001, respectively. Although HTN was more prevalent among adults than children, children were more likely to be categorized as hypertensive uncontrolled (Table 1) .
Comparing by disease cohort, there was a significant difference in prevalence of HTN across the disease groups in adults but not in children (Table 2) . Disease cohort was significantly associated with HTN after adjustment for age, sex, race, weight status, edema, steroids, CNI, eGFR, and smoking (adults) in adults (P=0.036) but not in children (P=0.9). For adults, the odds of HTN were 5.5× greater in IgA and 3.8× greater in FSGS compared with MCD (Table 3) . *Hypertensive BP status defined as previous diagnosis of hypertension or elevated BP for age at the baseline visit; hypertensive uncontrolled defined as previous diagnosis of hypertension and elevated BP at the baseline visit.
†SBP/DBP index: BP was divided by the 95th percentile BP in children.
Treatment Patterns
Antihypertensive treatment by age group is shown in Table  S1 in the online-only Data Supplement. In contrast to adults, children more frequently were not treated with antihypertensive medications (43.5% versus 12.1%) at baseline (P<0.001).
Overall, RAAS blockade (65.1%) was most common followed by diuretics (35.7%) and calcium channel blockers (22.2%). A greater proportion of adults were taking each class of antihypertensive medication when compared with children (all P<0.05).
Blood Pressure Variability
There were 378 (85.3%) participants with ≥3 BP readings over separate visits during the first year of participation in NEPTUNE from which visit-to-visit BPV was calculated. Adults had significantly greater systolic SD and ARV compared with children (Table 1 ). There was no significant difference in these parameters by disease cohort (Table 2) . Variables were assessed in regression models to examine determinants of BPV in adults and children. In adults, black race (β=2.8; 95% CI, 0.65-4.9; P=0.01) and baseline systolic BP (β=0.08; 95% CI, 0.03-0.13; P=0.004) were significantly associated with systolic SD in the multivariable model adjusting for age, sex, race, weight status, and edema. Black race was also associated with systolic ARV in adults (β=3.6; 95% CI, 0.67-6.6; P=0.02). In children, baseline systolic BP was directly related to systolic SD (β=0.23; 95% CI, 0.15-0.3; P<0.0001) and systolic ARV (β=0.2; 95% CI, 0.12-0.3; P<0.0001). Disease cohort, antihypertensive medication class, immunosuppression, weight status, and edema were not associated with BPV in adults or children.
Hypertensive BP Status and BPV with Outcomes
Overall, after a median of 2 years of follow-up, there were 212 complete remission ever events (129/296 in adults and 83/147 in children) and 91 composite end point events (69/296 in adults and 22/147 in children).
In adults, HTN was significantly associated with a lower hazard of complete remission ever (P<0.001) in models 1 and 2 (Table 4; Figure S1 ). HTN was also associated with a 4.1× greater hazard of reaching the composite end point only in the more parsimonious model 1 (Figure) . There was no association of baseline HTN with eGFR slope. Greater systolic and diastolic BPVs were associated with a greater hazard of reaching the composite end point (Table 4) . For each 1 U increase in systolic SD, there was a 5% increase in the occurrence of the composite end point (model 1). For systolic ARV, there was a 10% increase in composite end point for each 1 U increase (model 1). In children, HTN trended toward lower hazard of complete remission ever in model 1, but failed to reach statistical significance (Table 5) . HTN was not associated with eGFR slope or composite end point in children. Greater systolic SD and ARV were associated with a greater hazard of reaching the composite end point in model 1. Systolic and diastolic ARV were also associated with a lower hazard of complete remission ever in children (Table 5 ).
Discussion
In this large cohort of adults and children with primary proteinuric glomerulopathies, nearly 60% of participants had HTN at enrollment. Although HTN was more prevalent among adults, children were more often categorized as having uncontrolled BP. Treatment with antihypertensive medication was common, although less so in children compared with adults. Of the various antihypertensive classes, RAAS blockade was the most commonly prescribed, with two thirds of the population overall treated with these agents. In adults, HTN was associated with lower odds of complete remission ever and greater hazard of reaching the composite end point of ESRD or eGFR decline by ≥40%. Adults had significantly greater BPV as determined by systolic SD and ARV when compared with children, and these measures, along with diastolic SD and ARV, were associated with a greater hazard of reaching the composite end point in adults. In children, BPV was also associated with greater hazard of reaching the composite end point (as determined by systolic SD and ARV) and with a lower hazard of reaching complete remission ever (as determined by systolic and diastolic ARV).
Although nephrotic syndrome is known to be associated with increased cardiovascular risk, there is little information on the prevalence of hypertension and antihypertensive treatment patterns in adults and children with primary proteinuric glomerulopathies associated with nephrotic syndrome. We found that HTN was more common in adults than in children. In agreement with our findings, a smaller study of individuals with FSGS also described a substantial hypertension prevalence: 76% in adults and 44% in children. 21 In other smaller studies of children, hypertension before corticosteroid therapy was reported to be uncommon in MCD but was found in 20% to 50% of children with FSGS at the time of diagnosis. 22, 23 Prevalence rates of hypertension as determined by 24-hour ambulatory BP monitoring vary in the literature, ranging from 14% to 89%. [24] [25] [26] Our finding of a higher prevalence of HTN in adults compared with children could possibly be explained by the higher baseline prevalence of essential hypertension found in the general adult population and lower eGFR in adults compared with children in this cohort. Surprisingly, we found that disease cohort was not associated with HTN in children, whereas FSGS and IgA were determinants of HTN in adults. This finding in children could possibly be explained by the almost universal use of steroid/CNI treatment in children regardless of disease cohort. In addition, we observed that BP was treated more aggressively in adults than in children. As expected, RAAS blockade was the most used class of antihypertensive medications, likely owing its antiproteinuric effects.
There is also a paucity of data on the relationship of hypertension with clinical outcomes in primary proteinuric glomerulopathies. Our findings support our hypothesis that HTN is associated with worse clinical outcomes in adults with proteinuric glomerulopathies. We demonstrate that adult hypertensive BP status is associated both with the development of ESRD and with a decline in eGFR of ≥40%. Data from the CRIC (Chronic Renal Insufficiency Cohort) support that hypertension is associated with progression of renal disease and ESRD; however, the cohort includes various causes of kidney disease. 27 The scant reports on primary glomerulopathies are conflicting. Moranne et al 28 reported that baseline hypertension was not predictive of ESRD in those of primary glomerulonephritis, whereas Chou et al 29 showed that baseline hypertension in IgA nephropathy (but not in membranous nephropathy or FSGS) was associated with progression to ESRD. Interestingly, Zagury et al 23 showed that hypertension was associated with increased risk for developing ESRD in children with steroid-resistant nephrotic syndrome. Although this is in contrast to our findings, where we did not find HTN to be associated with poorer outcomes in children, it should be noted that the article by Zagury et al 23 was not an adjusted analyses and was limited to children with steroid resistance.
BPV is emerging as an important CVD risk factor, with evidence suggesting that it is associated with clinical outcomes. [3] [4] [5] [6] Recent literature suggests that visit-to-visit BPV also has promise in predicting renal outcomes. In the ALLHAT study (Anti-Lipid Lowering Heart Attack Trial) of 21 245 hypertensive adults, greater visit-to-visit BPV was associated with incident ESRD and ≥50% decline in eGFR independent of mean BP. 5 Yano et al 30 described the association of longterm visit-to-visit BPV with the development of chronic kidney disease in a large Japanese population. A smaller study also in Japan demonstrated that increased visit-to-visit BPV was associated with albuminuria. 7 In this study, we provide evidence that this association of BPV to renal outcomes can be extended to primary glomerulopathy populations throughout the lifespan. Our findings also demonstrate that adults have significantly greater systolic SD and ARV compared with children, which is not surprising given that BPV has been shown to increase with mean BP and age. 31 Interestingly, disease cohort, clinical characteristics (weight and edema), and treatment (antihypertensive medication class and immunosuppressive medications) were not associated with BPV in adults or children.
There are limitations to this study that should be taken into consideration. Ideally, hypertension is defined by the measurement of elevated BP from at least 2 (adults) or 3 (children) separate office visits. 11, 12 Guidelines further recommend that auscultation is the preferred method of BP measurement over oscillometry. 11 The use of 24-hour ambulatory BP monitoring is also increasingly recommended for the diagnosis of hypertension. 32 In this study, we used previous medical history and the average of 2 seated oscillometric BPs from the baseline visit to determine hypertensive BP status. As a result, our findings may be subject to BP misclassification. However, if normotensive patients were mislabeled as HTN, we would expect to find weaker associations of HTN with outcomes. Although available, longitudinal measurements of BP in this cohort were not used to define hypertension because of the confounding of antihypertensive medication use over time that could have potentially affected BP. This is particularly relevant for this patient population because many are likely prescribed RAAS blockade for treatment of proteinuria. Second, although this study focuses on the association of baseline hypertension and BPV with outcomes, the relationship between BP, proteinuria cause, and renal outcomes may not necessarily be causal, especially given the observational nature of the study. However, the renal outcomes evaluated were restricted to a period after the measurement of BPV. An additional limitation is that treatment with antihypertensive medications was not stable throughout the study duration; therefore, greater BPV in these patients could be a reflection of changes in BP control caused by medications (ie, patients with higher BP at study initiation could potentially be those who experienced the greatest fall in BP over time, which in turn affects BPV). It should be noted though that baseline BP and use of RAAS blockade were adjusted for in the regression models for renal outcomes. Last, all the NEPTUNE sites are academic centers where practices of BP management may differ from nonacademic institutions, thereby possibly affecting the generalizability of our results.
Perspectives
In summary, HTN is common among the adults and children with primary proteinuric glomerular diseases enrolled in NEPTUNE. There were significant differences in the prevalence of HTN, BPV, and treatment by age and disease cohort. HTN and greater BPV were associated with poorer renal outcomes, which may have clinical implications. These observations highlight the importance of further research, including clinical trials, to determine the impact of improved BP control on renal and CVD outcomes among individuals with primary proteinuric glomerular disease. Model 1 includes age at baseline, sex, race, disease cohort, and follow-up time. Model 2 includes model 1+calcineurin inhibitor/steroid use, renin-angiotensin-aldosterone system use, weight status, edema, cholesterol, SBP index, and eGFR. ARV indicates average real variability; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HTN, hypertensive blood pressure status; SBP, systolic blood pressure; and UPC, urine protein creatinine.
*Model 2 failed to converge (ie, there was no maximum to the maximum likelihood function because there were variables in which there were no observations for exposure levels among the cases and controls.)
